The things most lucrative to pharma are problems whose number of affected patients (x axis) and price to treat (y axis) create a box with the highest volume on a graph. That is, things which are expensive to treat, yet treatable, which many people have (common, not rare). Things like diabetes, cancer, etc. I don't think Hashimoto's thyroiditis would fall into that category.